Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 21, 2026 02:30 ET | Source: Enterome

Enterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with progression-free survival in patients with indolent non-Hodgkin lymphoma in the watch-and-wait setting

Enterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with PFS in patients with iNHL in the watch-and-wait setting
July 15, 2026 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors

ALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2 Regimen in Patients with Stage IV Renal Cell Carcinoma (RCC) with High CD70 Expression Single Dose of ALLO-316 Produced...
July 13, 2026 08:00 ET | Source: Enlivex Ltd.

Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis

FDA grant of RMAT designation to Allocetra™ reinforces the potential of this program to deliver a meaningful, disease-modifying impact in age-related primary knee osteoarthritis, where patients face...
July 08, 2026 16:05 ET | Source: Candel Therapeutics

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
July 08, 2026 08:30 ET | Source: Vaccinex, Inc.

Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026

Vaccinex reports new biomarker research and plans for Phase 2 randomized clinical trial of pepinemab in Alzheimer's Disease at the AAIC in July
July 06, 2026 15:00 ET | Source: Alberta Cancer Foundation

Alberta Cancer Foundation invests $35-million to power cancer clinical trials for Albertans

The Alberta Cancer Foundation is investing $35-million to advance cancer clinical trials in Alberta.
July 03, 2026 05:11 ET | Source: Research and Markets

Rituximab Market Growth Driven by Multi-Indication Use in Oncology and Autoimmune Diseases

Dublin, July 03, 2026 (GLOBE NEWSWIRE) -- The "Rituximab Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. Key Factors Driving Rituximab...
July 01, 2026 16:05 ET | Source: Candel Therapeutics

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
June 09, 2026 06:00 ET | Source: Treos Bio Corp.

TREOS Bio Presents New PEPI Technology Data at EACR 2026, Including Six-Year Cancer-Free Outcome in MSS Metastatic Colorectal Cancer (mCRC)

LONDON and BOSTON and BUDAPEST, Hungary, June 09, 2026 (GLOBE NEWSWIRE) -- Treos Bio, a clinical-stage company developing off-the-shelf and personalized active cancer immunotherapies, today...
June 05, 2026 11:48 ET | Source: EnGeneIC

EnGeneIC Honored with 2026 Breakthrough in Glioblastoma Biotech Award at Northwell Foundation Lenox Hill Neurosurgery Brain Cancer Gala in New York

EnGeneIC Honored with 2026 Breakthrough in glioblastoma Biotech Award at Northwell Foundation Lenox Hill Neurosurgery Brain Cancer Gala in New York